Epigenomics AG / Key word(s): Capital Increase
27.10.2013 19:59
Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Berlin, Germany, October 27, 2013 - Epigenomics AG (ISIN: DE000A1K0516)
announces that BioChain and certain of its shareholders will invest US$ 1.3
million (EUR 0.94 million) into the Company by subscribing 217,935 newly
issued shares. This investment follows the signing of an agreement
regarding a broad strategic collaboration of both companies announced
today. Executive Board and Supervisory Board of Epigenomics today approved
the increase of the share capital of the company from authorized capital
against contribution in cash. The issue price has been set at EUR 4.32 per
share. This constitutes a 5% discount to the two-day XETRA closing price
average prior to the announcement. After registration of the capital
increase, the subscribed capital of Epigenomics AG will increase from
currently EUR 12,118,192 to EUR 12,336,127.
Epigenomics AG intends to use the net proceeds from the offering to finance
its current operations and to strengthen the distribution capabilities,
especially for its lead product Epi proColon(R), a blood-based test for the
early detection of colorectal cancer.
- End of Ad hoc -
Contact Epigenomics AG
Antje Zeise CIRO
Manager IR | PR
Epigenomics AG
Phone: +49 (0) 30 24345 386
ir@epigenomics.com
www.epigenomics.com
Epigenomics' legal disclaimers. This communication expressly or implicitly
contains certain forward-looking statements concerning Epigenomics AG and
its business. Such statements involve certain known and unknown risks,
uncertainties and other factors which could cause the actual results,
financial condition, performance or achievements of Epigenomics AG to be
materially different from any future results, performance or achievements
expressed or implied by such forward-looking statements. Epigenomics AG is
providing this communication as of this date and does not undertake to
update any forward-looking statements contained herein as a result of new
information, future events or otherwise.
The information contained in this communication does not constitute nor
imply an offer to sell or transfer any product, and no product based on
this technology is currently available for sale by Epigenomics in the
United States or Canada. The analytical and clinical performance
characteristics of any Epigenomicsproduct based on this technology which
may be sold at some future time in the U.S. have not been established.
27.10.2013 DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Epigenomics AG
Kleine Präsidentenstraße 1
10178 Berlin
Germany
Phone: +49 30 24345-0
Fax: +49 30 24345-555
E-mail: ir@epigenomics.com
Internet: www.epigenomics.com
ISIN: DE000A1K0516
WKN: A1K051
Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
in Berlin, Düsseldorf, München, Stuttgart
End of Announcement DGAP News-Service
---------------------------------------------------------------------------
27. October 2013 - 0:00 (CEST)